Magritek adds NexMR to bring photohyperpolarization to benchtop NMR

Magritek said July 14, 2026 that NexMR is joining the group to integrate photohyperpolarization technology into the Spinsolve platform. The move could make benchtop NMR biophysics more accessible and expand what compact instruments can measure, with first systems expected within 12 months.

Why it matters: - NexMR's photohyperpolarization technology could make NMR biophysics usable on benchtop systems without the cost and complexity of traditional hyperpolarization hardware. - The integration into Magritek's Spinsolve platform could open lower-signal applications such as low-concentration samples and fast reaction monitoring on compact instruments. - Magritek and NexMR said the combination pushes benchtop NMR further into applications that were previously out of reach.

What happened: - Magritek announced July 14, 2026 that NexMR is joining the Magritek group. - The announcement came from Aachen, North Rhine-Westphalia, Germany. - Magritek said the move brings NexMR's photohyperpolarization science into the company best positioned to develop it and distribute it worldwide. - Terms of the deal were not disclosed.

The details: - Magritek built the benchtop NMR category and has set its technological standard for years. - NexMR develops advanced photohyperpolarization technology. - Photohyperpolarization boosts signal strength by orders of magnitude. - The approach does not require the cost and complexity of traditional hyperpolarization hardware. - The technology is being integrated into Magritek's Spinsolve platform. - The integration is meant to enable measurements on compact instruments that were previously not possible. - Magritek said development of the first hyperpolarization-enabled systems is already underway. - Availability is expected within 12 months. - Magritek was founded in 2004 and is headquartered in Wellington, New Zealand, with operations in Aachen and Philadelphia. - Magritek's Spinsolve platform provides high-resolution, multinuclear NMR for pharmaceutical, chemical, polymer, food and energy industries, plus academic research and education. - NexMR AG is a Swiss biotechnology company focused on photo-CIDNP NMR for pharmaceutical research and fragment-based drug discovery. - NexMR developed the CRIO-X platform for light-coupled NMR screening on benchtop and high-field instruments. - NexMR holds an exclusive worldwide license from ETH Zurich for its core technology. - More information is available on Félix Torres' LinkedIn profile.

Between the lines: - The deal pairs a category leader in benchtop NMR with a specialist in a potentially enabling technology, which suggests Magritek wants to defend and extend its lead through product innovation. - The comments from both CEOs frame the transaction as a strategic fit rather than a simple acquisition. - The announcement signals that biophysics and screening workflows may move closer to routine use on benchtop systems if the integration performs as described.

What's next: - Magritek said the first hyperpolarization-enabled systems are in development now. - Customers should expect availability within 12 months. - The next milestone is proving the technology inside the Spinsolve platform and bringing it to researchers worldwide.